Viridian Therapeutics, Inc. (0K1R.L) LSE

Currency In USD

AD

Valuation

Market Cap2.64B
Enterprise Value2.48B
P/E Ratio-6.88
PEG Ratio-0.76
Price/Sales Ratio38.69
Price/Book Ratio3.96
Enterprise/Revenue39.78
Enterprise/EBITDA-7.55

Fiscal Year

Fiscal YearDecember 31, 2025
Most Recent QuarterJune 30, 2026

Profitability

Profit Margin-5.44
Operating Margin-5.7
AD

Management Effectiveness

Return On Assets-0.35
Return On Equity-0.61

Income Statement

Revenue70.85M
Revenue/Share0.66
Gross Profit69.69M
EBITDA-362.24M
Net Income-342.6M
Diluted EPS-3.32

Balance Sheet

Total Cash981.53M
Total Cash/Share9.1
Total Debt242.88M
Total Debt/Equity0.37
Current Ratio16.95
Book Value Per Share6.14

Price History

52-Week Change25.76
52-Week High29.3
52-Week Low10.98
Moving Average 50 Days20.02
Moving Average 200 Days19.53

Statistics

Average Volume682
Shares Outstanding90M
% Held by InstitutionsN/A

Dividend And Splits

Trailing Annual Dividend Rate0
Trailing Annual Dividend Yield0
Payout Ratio0
Last Split Factor1:15
Last Split DateSeptember 21, 2021
AD